Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
211
-
Total 13F shares, excl. options
-
77.7M
-
Shares change
-
+1.54M
-
Total reported value, excl. options
-
$4.44B
-
Value change
-
+$73.6M
-
Put/Call ratio
-
0.32
-
Number of buys
-
113
-
Number of sells
-
-92
-
Price
-
$57.10
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q1 2021
250 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q1 2021.
Denali Therapeutics Inc. - Common Stock (DNLI) has 211 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.7M shares
of 145M outstanding shares and own 53.5% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (13M shares), Crestline Management, LP (9.98M shares), VANGUARD GROUP INC (8.17M shares), BlackRock Inc. (6.56M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.06M shares), Temasek Holdings (Private) Ltd (4.41M shares), GILDER GAGNON HOWE & CO LLC (3M shares), FMR LLC (2.69M shares), STATE STREET CORP (2.02M shares), and CREDIT SUISSE AG/ (1.96M shares).
This table shows the top 211 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.